Abstracts tagged "Autoantibody(ies)"

Abstract Number: 1022 • ACR Convergence 2021
Incidence of Antisynthetase Syndrome and Risk of Malignancy in a Population-based Cohort (1998-2019)
Caitrin Coffey¹, Li Wang¹, Stephanie Duong¹, Cassondra Hulshizer¹, Cynthia Crowson², Jay Ryu¹ and Floranne Ernste¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The antisynthetase syndrome (ASSD) is a distinct subgroup of the idiopathic inflammatory myopathies characterized by myositis, interstitial lung disease, inflammatory arthritis, Raynaud’s phenomenon and…
Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Nilasha Ghosh¹, Deanna Jannat-Khah², Karmela Kim Chan², Michael Postow³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Memorial Sloane Kettering Cancer Center, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 0089 • ACR Convergence 2021
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
Hannah Mathew¹, May Choi², Katherine Buhler¹, Ann Clarke¹, Xenia Gukova¹, Francesca Cardwell³ and Marvin Fritzler¹, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³University of Waterloo, Waterloo, ON, Canada
Background/Purpose: At the outset of the SARS-CoV-2 pandemic, it was speculated that SLE patients may be at significant risk of developing COVID-19 due to underlying…
Abstract Number: 0553 • ACR Convergence 2021
IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study
Aurélien Chepy¹, Solange Vivier², Fabrice Bray³, Martin Figeac⁴, Jean-Pascal Meneboo⁴, Camille Ternynck⁵, Lucile Guilbert², Manel Jendoubi², Christian Rolando³, David Launay¹, Sylvain Dubucquoi⁶, Guillemette Marot⁵ and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, ²Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille, France, ³Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse, l'Analyse et la Protéomique, F-59000 Lille, France, Lille, France, ⁴Université de Lille, Functional Genomics Platform, Lille, France., Lille, France, ⁵ULR 2694 – METRICS : évaluation des technologies de santé et des pratiques médicales, université de Lille, CHU de Lille, 59000 Lille, France, Lille, France, ⁶Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille
Background/Purpose: Antinuclear antibodies are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is much more debated. This study explored the…
Abstract Number: 1089 • ACR Convergence 2021
Clinical Associations of Anti-Ro52 Antibodies in Patients with Systemic Autoimmune Rheumatic Diseases
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Anti-SSA/Ro antibodies (Abs) can target Ro60 and Ro52 antigens. The presence of anti-Ro60 Abs has been widely described in patients with systemic autoimmune rheumatic…
Abstract Number: 1521 • ACR Convergence 2021
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Nilasha Ghosh¹, Chengsong Zhu², Karmela Kim Chan³, Michael Postow⁴ and Anne Bass⁵, ¹Hospital for Special Surgery, New York, NY, ²UT Southwestern, Dallas, TX, ³Hospital for Special Surgery, New York, NY, ⁴Memorial Sloane Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 0001 • ACR Convergence 2021
Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA Synthetase Family in Idiopathic Inflammatory Myopathies
Charlotta Preger¹, Antonella Notarnicola¹, Cecilia Hellström², Edvard Wigren¹, Catia Cerqueira³, Peter Nilsson², Ingrid E Lundberg¹, Helena Persson⁴, Susanne Gräslund¹ and Per-Johan Jakobsson⁵, ¹Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ²Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ³4Dcell, Montreuil, France, ⁴Drug Discovery and Development Platform, SciLifeLab & School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Solna, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoantibodies are thought to play a key role in the pathogenesis of idiopathic inflammatory myopathies (IIM). However, 40% of IIM patients, even those with…
Abstract Number: 0150 • ACR Convergence 2021
Clinical Characteristics and Quantitative CT Findings in Connective Tissue Disease-Associated Interstitial Lung Disease
Sirus Jesudasen¹, Badar Patel², Kristin D'Silva¹, Pietro Nardelli², Ruben San José Estépar², George Washko², Raúl San José Estépar², Farbod Rahaghi² and Sydney Montesi¹, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Precapillary Pulmonary Hypertension (PPH) is a known complication of connective tissue disease-associated interstitial lung disease (CTD-ILD) but at present requires right heart catheterization (RHC)…
Abstract Number: 0618 • ACR Convergence 2021
Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases
Alice Fike¹, Omer Pamuk², Yiming Luo³, Jun Chu⁴, Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Pravitt Gourh³ and James Katz⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²NIH/NIAMS, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
Abstract Number: 1526 • ACR Convergence 2021
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Chathura Wijewardena¹, Paramarajan Pirinavan¹, Sandy Nasr¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of…
Abstract Number: 0006 • ACR Convergence 2021
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
Ivan Ramirez¹, Betty Diamond² and Sun Jung Kim³, ¹Northwell, Little Neck, NY, ²Northwell Health, Manhasset, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…
Abstract Number: 0155 • ACR Convergence 2021
The Additional Value of MRI in Diagnosis of Rheumatoid Arthritis in Undifferentiated Arthritis Patients
Nikolet den Hollander¹, Marloes Verstappen¹, Navkiran Sidhu¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Identifying patients that will develop rheumatoid arthritis (RA) among those presenting with undifferentiated arthritis (UA) remains a clinical dilemma. According to EULAR recommendations magnetic…
Abstract Number: 0687 • ACR Convergence 2021
Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
Christopher Mecoli¹, Eleni Tiniakou², William Kelly², Jemima Albayda², Julie Paik², Brittany Adler², Andrew Mammen³, Cheng Ting Lin¹, Sonye Danoff⁴, Livia Casciola-Rosen⁵ and Lisa Christopher-Stine², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴Johns Hopkins Medicine, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD
Background/Purpose: We describe a single-center North American adult cohort of MDA5-positive DM, with emphasis on the subgroup of patients that experience drug-free long-term remission. Methods:…
Abstract Number: 1101 • ACR Convergence 2021
Atypical Pulmonary Radiographic Findings May Help Identify Patients with Usual Interstitial Pneumonia and Autoimmune Features
Fredeswinda Romero Bueno¹, Carmelo Palacios¹, Maria Jesus Rodriguez Nieto¹, Maria Tello Lasheras¹, Angel Rodriguez Leon², Maria Carmen Vegas Sanchez¹, Gabriel Herrero-Beaumont³ and Olga Sanchez Pernaute¹, ¹University Hospital "Fundación Jimenez Diaz", Madrid, Spain, ²Autonoma University of Madrid, Madrid, Spain, ³University Hospital "Fundacion Jimenez Diaz", Madrid, Spain
Background/Purpose: Once specific etiologic factors have been ruled out, the majority of patients with chronic interstitial pneumonia (IP) can be classified as idiopathic pulmonary fibrosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].